SABCS roundup: Novartis shows two-year PFS in breast cancer subgroups; AstraZeneca reveals more Enhertu data

The San Antonio Breast Cancer Symposium is taking place this week, and so far, some of the Big Pharmas are turning out new trial data about some of the biggest drugs in the space.

First off, Novartis announced that its drug, Kisqali, showed about a year of progression-free survival in patients…